ALEXANDER, G. E. AND CRUTCHER, M. D.: Functional architecture of basal ganglia
circuits: neural substrates of parallel processing. Trends Neurosci. 13: 266–
271, 1990.
ALTAR, C. A. AND HAUSER, K.: Topography of substantia nigra innervation by D1
receptor-containing striatal neurons. Brain Res. 410: 1–11, 1987.
ARNT, J.: Antistereotypic effects of dopamine D-2 and D-2 antagonists after
intrastriatal injection in rats. Pharmacological and regional specificity. Naunym-Schmiedeberg Arch. Pharmacol. 330: 97–104, 1985.
BARUSH, P. F., ARTAND, F., GODEHEN, G., BARBEITO, L., GLOWINSKI, J. AND CHERAMY, A.: Substance P and neurokinin a regulate by different mechanisms
dopamine release from dendrites and nerve terminals of the nigrostriatal
dopaminergic neurons. Neuroscience 25: 889–898, 1988.
BAUMEISTER, A. A. AND FRYE, G.: Self-injurious behavior in rats produced by
intranigral microinjection of GABA agonists. Pharmacol. Biochem. Behav.
21: 89–95, 1984.
BECKSTEAD, R. M., DOMESTICK, V. B. AND NAUTA, W. J. H.: Efferent connections
of the substantia nigra and ventral tegmental area in the rat. Brain Res.
175: 191–217, 1979.
BISCHOFF, S., HEINRICH, M., SONNTAG, J. AND KRAUS, J.: The D-1 dopamine
receptor antagonist SCH23390 also interacts potently with brain seotonin
(5-HT2) receptors. Eur. J. Pharmacol. 129: 367–370, 1986.
BJO ̈ RKLUND, A. AND LINDVALL, O.: Dopamine-containing system in the CNS. In
Handbook of Chemical Neuroanatomy, Vol. 2, Classical Transmitter in the
CNS, Part I, ed. by Bjo ̈rklund, A. and Ho ̈kfelt, T., pp. 55–122, Elsevier,
Amsterdam, 1984.
BLANCHARD, V., RAISMAN-BOZARI, R., VYAS, S., MICHEL, P., JAVOY-AGID, F., UHL, G.
AND AGID, Y.: Differential expression of tyrosine hydroxylase and membrane
dopamine transporter genes in subpopulations of the rat mesencephalon.
Mol. Brain Res. 22: 29–40, 1994.
BREESE, G. R., BAUMEISTER, A., NAPIER, T. C., FRYE, G. D. AND MUELLER, R. A.:
Evidence that D-1 dopamine receptors contribute to the supersensitive be- havioral responses induced by L-dihydroxydopamine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235: 287–295, 1985.
BREESE, G. R., BAUMEISTER, A. A., MCCOWN, T. J., EMERICK, S. G., FRYE, G. D.,
CROTTY, K. AND MUELLER, R. A.: Behavior differnces between neonatal and
adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to
neurological system in clinical sundromes with reduced brain dopamine.
J. Pharmacol. Exp. Ther. 235: 287–295, 1984.
BREESE, G. R., CRISWELL, H. E., DUNCAN, G. E. AND MUELLER, R. A.: A dopamine
deficiency model of Lesch-Nyhan disease—The neonatal-6-OHDA-lesioned
rat. Brain Res. Bull. 25: 477–484, 1990.
BREESE, G. R., DUNCAN, G. E., NAPIER, T. C., BONDY, S. C., IORIO, L. C. AND
MUELLER, R. A.: 6-Hydroxydopamine treatments enhance behavioral re- sponse to intracerebral microinjection of D1- and D2-dopamine agonists into
nucleus accumbens and striatum without changing dopamine antagonist
binding. J. Pharmacol. Exp. Ther. 240: 167–176, 1987a.
BREESE, G. R., HULEBAK, K. L., NAPIER, T. C., BAUMEISTER, A., FRYE, G. AND
MUELLER, R. A.: Enhanced muscimol-induced behavioral responses after
6-OHDA lesions: relevant to susceptibility for self-mutilation behavior in
neonatal lesioned rats. Psychopharmacology 91: 356–362, 1987b.
BURNS, R. S., CHIEUH, C. C., MARKEY, S. P., EBERT, M. H., JACOBOWITZ, D. M. AND
KOPIN, I.: A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80: 4546–
4550, 1983.
CABOCHE, J., ROGARD, M. AND BESSON, M.-J.: Comparative development of D1- dopamine and m opiate receptors in normal and 6-hydroxydopaminelesioned neonatal striatum: dopaminergic fibers regulate m but not D1
receptor distribution. Dev. Brain Res. 58: 111–122, 1991.
CAMERON, D. L. AND WILLIAMS, J. T.: Dopamine D1 receptors facilitate transmitter release. Nature 366: 344–347, 1993.
CERRUTTI, C., WALTHER, D. M., KUHAR, M. J. AND UHL, G. R.: Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest
outside midbrain. Mol. Brain Res. 18: 181–186, 1993.
CHERAMY, A., LEVIEL, V. AND GLOWINSKI, J.: Dendritic release of dopamine in the
substantia nigra. Nature 289: 537–542, 1981.
CHRISTIE, R., BAY, C., KAUFMAN, I. A., BAKAY, B., BORDEN, M. AND NYHAN, W. L.:
Lesch-Nyhan disease: Clinical experience with nineteen patients. Dev. Med.
Child Neurol. 24: 293–306, 1982.
DAHLSTO ̈ M, A. AND FUXE, K.: Evidence of the existence of monoamine containing
neurons in the central nervous system. 1. Demonstration of monoamines in
the cell bodies of brain stem neurons. Acta Physiol. Scand. 62(Suppl. 232):
1–55, 1964.
DEMAREST, K. T. AND MOORE, K. E.: Lack of high affinity transport system for
dopmaine in the median eminence and posterior pituitary. Brain Res. 171:
545–551, 1979.
DESCARRIES, L., SOGHOMONIAN, J. J., GARCIA, S., DOUCET, G. AND BRUNO, J. P.:
Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine.
Brain Res. 569: 1–13, 1992.
DEWAR, K. M., SOGHOMONIAN, J.-J., BRUNO, J. P., DESCARRIES, L. AND READER, T.
A.: Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum
after neonatal 6-hydroxydopamine denervation. Brain Res. 536: 287–296,
1990.
DUNCAN, G. E., BREESE, G. R., CRISWELL, H. E., JOHNSON, K. B., SCHAMBRA, U. B.,
